Rallybio Corporation (RLYB)

Rallybio Statistics

Total Valuation

Rallybio has a market cap or net worth of $22.15 million. The enterprise value is -$23.78 million.

Market Cap	22.15M
Enterprise Value	-23.78M

Important Dates

The last earnings date was Thursday, August 7, 2025, before market open.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Rallybio has 41.79 million shares outstanding. The number of shares has increased by 7.72% in one year.

Current Share Class	41.79M
Shares Outstanding	41.79M
Shares Change (YoY)	+7.72%
Shares Change (QoQ)	+0.15%
Owned by Insiders (%)	4.14%
Owned by Institutions (%)	26.52%
Float	19.86M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	29.60
Forward PS	n/a
PB Ratio	0.46
P/TBV Ratio	0.48
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.98, with a Debt / Equity ratio of 0.00.

Current Ratio	9.98
Quick Ratio	9.08
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -66.12% and return on invested capital (ROIC) is -41.26%.

Return on Equity (ROE)	-66.12%
Return on Assets (ROA)	-36.34%
Return on Invested Capital (ROIC)	-41.26%
Return on Capital Employed (ROCE)	-90.73%
Revenue Per Employee	$30,440
Profits Per Employee	-$1.67M
Employee Count	25
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -55.88% in the last 52 weeks. The beta is -1.11, so Rallybio's price volatility has been lower than the market average.

Beta (5Y)	-1.11
52-Week Price Change	-55.88%
50-Day Moving Average	0.41
200-Day Moving Average	0.66
Relative Strength Index (RSI)	54.94
Average Volume (20 Days)	563,233

Short Selling Information

The latest short interest is 1.35 million, so 3.22% of the outstanding shares have been sold short.

Short Interest	1.35M
Short Previous Month	1.98M
Short % of Shares Out	3.22%
Short % of Float	6.78%
Short Ratio (days to cover)	0.18

Income Statement

In the last 12 months, Rallybio had revenue of $761,000 and -$41.65 million in losses. Loss per share was -$0.93.

Revenue	761,000
Gross Profit	-38.63M
Operating Income	-41.70M
Pretax Income	-73.88M
Net Income	-41.65M
EBITDA	-41.59M
EBIT	-41.70M
Loss Per Share	-$0.93

Balance Sheet

The company has $45.75 million in cash and $58,000 in debt, giving a net cash position of $45.69 million or $1.09 per share.

Cash & Cash Equivalents	45.75M
Total Debt	58,000
Net Cash	45.69M
Net Cash Per Share	$1.09
Equity (Book Value)	45.96M
Book Value Per Share	1.10
Working Capital	45.23M

Cash Flow

Operating Cash Flow	-41.99M
Capital Expenditures	n/a
Free Cash Flow	-41.99M
FCF Per Share	-$1.00

Margins

Gross Margin	n/a
Operating Margin	-5,479.76%
Pretax Margin	-5,473.32%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Rallybio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.72%
Shareholder Yield	-7.72%
Earnings Yield	-190.12%
FCF Yield	-191.66%

Analyst Forecast

The average price target for Rallybio is $15.00, which is 2,730.19% higher than the current price. The consensus rating is "Hold".

Price Target	$15.00
Price Target Difference	2,730.19%
Analyst Consensus	Hold
Analyst Count	3
Revenue Growth Forecast (5Y)	261.73%
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Rallybio has an Altman Z-Score of -6 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6
Piotroski F-Score	3